• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Stimulating hypocretin receptors improves sleepiness and vigilance in idiopathic hypersomnia: lessons from a proof of concept study.刺激下丘脑分泌素受体可改善发作性睡病的嗜睡和警觉性：一项概念验证研究的经验教训。
Sleep. 2023 Sep 8;46(9). doi: 10.1093/sleep/zsad085.
2
Narcolepsy and Idiopathic Hypersomnia.发作性睡病与特发性嗜睡症。
Sleep Med Clin. 2023 Jun;18(2):183-199. doi: 10.1016/j.jsmc.2023.01.003. Epub 2023 Mar 8.
3
Pharmacologic Management of Excessive Daytime Sleepiness.日间过度嗜睡的药物治疗
Sleep Med Clin. 2020 Jun;15(2):177-194. doi: 10.1016/j.jsmc.2020.02.006.
4
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.丹那瑞酮单次输注治疗特发性嗜睡症成人患者的安全性和药效学。
Sleep. 2023 Sep 8;46(9). doi: 10.1093/sleep/zsad049.
5
Idiopathic Hypersomnia and Depression, the Challenge for Clinicians and Researchers.特发性嗜睡症与抑郁症：临床医生和研究人员面临的挑战
Prague Med Rep. 2021;122(3):127-139. doi: 10.14712/23362936.2021.13.
6
Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.特发性嗜睡症治疗进展：进展、挑战和专家意见。
Sleep Med Rev. 2023 Jun;69:101766. doi: 10.1016/j.smrv.2023.101766. Epub 2023 Feb 25.
7
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.开发一种低钠羟丁酸钠制剂用于治疗发作性睡病和特发性嗜睡症患者。
Expert Opin Drug Discov. 2022 Feb;17(2):109-119. doi: 10.1080/17460441.2022.1999226. Epub 2021 Nov 24.
8
Face validation and pharmacologic analysis of Sik3 mutant mouse as a possible model of idiopathic hypersomnia. Sik3 突变鼠作为特发性嗜睡症可能模型的面部验证和药理学分析。
Eur J Pharmacol. 2023 Sep 5;954:175877. doi: 10.1016/j.ejphar.2023.175877. Epub 2023 Jun 24.
9
Evaluation of pathological sleepiness by Multiple Sleep Latency Test and 24-hour polysomnography in patients suspected of idiopathic hypersomnia.通过多次睡眠潜伏期试验和24小时多导睡眠图对疑似特发性嗜睡症患者的病理性嗜睡进行评估。
Psychiatry Clin Neurosci. 2021 Apr;75(4):149-151. doi: 10.1111/pcn.13196. Epub 2021 Feb 13.
10
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.奥沙西泮治疗特发性嗜睡症成人患者的安全性和有效性：一项 3 期、安慰剂对照、双盲、随机撤药研究。
Lancet Neurol. 2022 Jan;21(1):53-65. doi: 10.1016/S1474-4422(21)00368-9.

本文引用的文献

1
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.食欲素 2 受体选择性激动剂丹那瑞克斯（TAK-925）可促进非人灵长类动物和健康个体的觉醒。
J Sleep Res. 2023 Oct;32(5):e13878. doi: 10.1111/jsr.13878. Epub 2023 Mar 19.
2
Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.特发性嗜睡症治疗进展：进展、挑战和专家意见。
Sleep Med Rev. 2023 Jun;69:101766. doi: 10.1016/j.smrv.2023.101766. Epub 2023 Feb 25.
3
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia.丹那瑞酮单次输注治疗特发性嗜睡症成人患者的安全性和药效学。
Sleep. 2023 Sep 8;46(9). doi: 10.1093/sleep/zsad049.
4
Clinical considerations for the diagnosis of idiopathic hypersomnia.发作性睡病的临床诊断考量
Sleep Med Rev. 2022 Dec;66:101709. doi: 10.1016/j.smrv.2022.101709. Epub 2022 Oct 31.
5
Precision Medicine for Idiopathic Hypersomnia.特发性发作性睡病的精准医学
Sleep Med Clin. 2022 Sep;17(3):379-398. doi: 10.1016/j.jsmc.2022.06.016. Epub 2022 Sep 8.
6
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.食欲素 2 受体选择性激动剂丹那瑞克斯改善了小鼠模型和人类患者的嗜睡症表型。
Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2207531119. doi: 10.1073/pnas.2207531119. Epub 2022 Aug 22.
7
Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering.基于无监督聚类的中枢性睡眠增多症的数据驱动表型分析。
Neurology. 2022 Jun 7;98(23):e2387-e2400. doi: 10.1212/WNL.0000000000200519. Epub 2022 Apr 18.
8
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.奥沙西泮治疗特发性嗜睡症成人患者的安全性和有效性：一项 3 期、安慰剂对照、双盲、随机撤药研究。
Lancet Neurol. 2022 Jan;21(1):53-65. doi: 10.1016/S1474-4422(21)00368-9.
9
Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study.莫达非尼治疗无长睡眠时相的特发性嗜睡症患者的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组比较研究。
Sleep Med. 2021 Apr;80:315-321. doi: 10.1016/j.sleep.2021.01.018. Epub 2021 Jan 20.
10
To split or to lump? Classifying the central disorders of hypersomnolence.分还是合？中枢性嗜睡症的分类。
Sleep. 2020 Aug 12;43(8). doi: 10.1093/sleep/zsaa044.

Stimulating hypocretin receptors improves sleepiness and vigilance in idiopathic hypersomnia: lessons from a proof of concept study.

作者信息

Arnulf Isabelle, Maranci Jean-Baptiste

机构信息

National Reference Center for Narcolepsy and Rare Hypersomnias, Sleep Clinic, Pitie-Salpetriere Hospital, APHP-Sorbonne University, Paris, France.

出版信息

Sleep. 2023 Sep 8;46(9). doi: 10.1093/sleep/zsad085.

DOI:10.1093/sleep/zsad085
PMID:37200618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10485564/
Abstract
摘要